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Abstract
Endothelial Cell Dysfunction (ECD) is a recognized harbinger of a host of chronic cardiovascular diseases. Using a mouse
model of ECD triggered by treatment with L-Nv-methylarginine (L-NMMA), we previously demonstrated that renal
microvasculature displays a perturbed protein profile, including diminished expression of two key enzymes of the Krebs
cycle associated with a Warburg-type suppression of mitochondrial metabolism. We hypothesized that supplementation
with L-glutamine (GLN), that can enter the Krebs cycle downstream this enzymatic bottleneck, would normalize vascular
function and alleviate mitochondrial dysfunction. To test this hypothesis, mice with chronic L-NMMA-induced ECD were co-
treated with GLN at different concentrations for 2 months. Results confirmed that L-NMMA led to a defect in acetylcholine-
induced relaxation of aortic rings that was dose-dependently prevented by GLN. In caveolin-1 transgenic mice characterized
by eNOS inactivation, L-NMMA further impaired vasorelaxation which was partially rescued by GLN co-treatment. Pro-
inflammatory profile induced by L-NMMA was blunted in mice co-treated with GLN. Using an LC/MS platform for metabolite
profiling, we sought to identify metabolic perturbations associated with ECD and offset by GLN supplementation. 3453
plasma molecules could be detected with 100% frequency in mice from at least one treatment group. Among these, 37
were found to be differentially expressed in a 4-way comparison of control vs. LNMMA both with and without GLN. One of
such molecules, hippuric acid, an ‘‘uremic toxin’’ was found to be elevated in our non-uremic mice receiving L-NMMA, but
normalized by treatment with GLN. Ex vivo analysis of hippuric acid effects on vasomotion demonstrated that it significantly
reduced acetylcholine-induced vasorelaxation of vascular rings. In conclusion, functional and metabolic profiling of animals
with early ECD revealed macrovasculopathy and that supplementation GLN is capable of improving vascular function.
Metabolomic analyses reveal elevation of hippuric acid, which may further exacerbate vasculopathy even before the
development of uremia.
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Introduction
Endothelial cell dysfunction (ECD) is a harbinger of multiple
cardiovascular diseases, as diverse as atherosclerosis, hypertension,
diabetes, to mention a few [1]. ECD is highly prevalent in chronic
kidneys diseases (CKD) where it is responsible for a sharp increase
in cardiovascular morbidity and mortality. Although ECD and
associated vascular abnormalities in patients with CKD have been
known for decades [2,3] their causes remain insufficiently
understood. It has been proposed that accumulation of homocys-
teine, overproduction of reactive oxygen species, and/or guani-
dine compounds and other uremic toxins are the culprits (rev in:
[4]). However, the fact that ECD develops at earlier, pre-uremic
stages of CKD effectively downplays the contribution of these
hypothetical culprits.
Perhaps the most powerful independent contributor to ECD is
asymmetric dimethylarginine (ADMA), which is elevated long
before the decline in GFR. This guanidino compound, fulfilling
many characteristics of ‘‘uremic toxin’’, is elevated in the course of
renal disease and has been found to be the second most valuable
(after the patient’s age) predictor of cardiovascular events and
mortality in CKD patients, as well as in general population [5,6].
This endogenous inhibitor of nitric oxide synthases (competing
with the substrate L-arginine) arises from the degradation of
methylarginine residues in proteins, generating daily .60 mg of
ADMA, of which 50 mg are metabolized by dimethylarginine
dimethylaminohydrolases (DDAH) and the rest is excreted in the
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urine [7,8]. Vascular endothelium is extremely sensitive to
ADMA: its infusion elevates blood pressure and peripheral
resistance at concentrations equivalent to those seen under
pathologic conditions [9].
Inhibition of eNOS and/or deficiency of bioavailable NO are
the most common and consistent causes of ECD leading to
vasculopathy and defective angiogenesis [10,11,12].
L-NMMA treatment, akin to the elevation in ADMA levels,
results in NOS uncoupling typified by enhanced generation of
superoxide and attenuated NO production [13]. Importantly,
increased generation of superoxide anion appears to be the
primary cause of the impaired vasorelaxation to acetylcholine in
the aorta of mice treated with sub-pressor dose of L-NMMA [14].
Our recent studies employing DIGE of isolated renal micro-
vasculature from L-NMMA-treated animals showed decreased
expression of 2 mitochondrial enzymes participating in oxidative
phosphorylation: aconitase-2 and enoyl-CoA hydratase-1, poten-
tially leading to truncation of the Krebs cycle and manifesting in
the normoxic inhibition of Krebs cycle and induction of glycolysis
– hallmarks of Warburg effect seen in tumor cells [15]. As in the
case of tumors, this was associated with elevated lactate levels in
the plasma.
In the present study, we argued that L-glutamine (GLN), a
precursor of a-ketoglutarate, and an FDA-approved nutritional
supplement used in critically ill patients, in intensive care units, in
patients with cancer and hematologic disorders [16,17,18] may
have beneficial effect on intermediary metabolism in the model of
chronic endothelial dysfunction. GLN is considered an essential
amino acid during certain diseases and in several stress situations
[19,20,21]. L-Glutamine plays a central and quantitatively
substantial role in the intermediary metabolism of carbon skeletons
and amino groups, and also serves as a precursor for other
important pathways. Deamination of glutamine yields NH3 and
glutamate which is dehydrogenated or transaminated in a-
ketoglutarate to enter in the Krebs cycle. Intestinal absorption of
GLN is maintained at 70–80%, and its plasma levels can be
monitored. Known effects of supplemental GLN are multiple:
improvement of glucose utilization in insulin resistance, stimula-
tion of HSP 70, anti-inflammatory and immunomodulatory
actions, enhancement of glutathione synthesis, and stimulation of
anabolic processes [22]. GLN is also an essential mitochondrial
substrate implicated in protecting cells from reactive oxygen
species, preserving a-ketoglutarate dehydrogenase activity and
enhancing cell ATP content [23]. GLN is considered a potent
anaplerotic molecule capable of replenishing intermediates of the
Krebs cycle [24,25] and its use for therapy of conditions where
Krebs cycle activation is desired has been advocated.
Based on this knowledge we hypothesized that L-glutamine
supplementation in mice chronically treated with non-pressor
doses of L-NMMA, a model of early ‘‘asymptomatic’’ endothelial
dysfunction [14,26,27] may serve to refuel the distal portion of
truncated Krebs cycle, with the possibility of restoring vascular
functions.
Materials and Methods
Ethics Statements
The animal study protocol was in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals and approved by the New York Medical College’s
Animal Care and Use Committee. The Laboratory Animal
Complex of the Comparative Medicine at the New York Medical
College is registered with the U.S. Department of Agriculture
(USDA) and the New York State Department of Health.
Animal Studies
Male FVB mice, aged 12 weeks, received a non-pressor dose of
L-NMMA (0.3 mg/kg/day) in drinking water for 2 months. A
randomly selected subgroup of these mice received glutamine
supplementation at concentrations 1, 10, and 30 mg/ml. Caveolin-
1 (2/2) and caveolin-1 overexpressing transgenic mice were
generated by Lisanti’s laboratory and treated similarly with L-
NMMA and glutamine supplementation. L-NMMA (NG-Mono-
methyl-L-arginine monoacetate, D-NNMA (NG-Monomethyl-D-
arginine.monoacetate), and ADMA (NG, NG-Dimethyl-L-arginine
dihydrochloride) were obtained from Alexis Biochemicals (San
Diego, CA). There were no differences in the initial body weight
among the groups, and the food intake or body weight after
chronic GLN or LNMMA feeding did not differ between the
groups. At the time of sacrifice, thoracic aortic rings were prepared
and the acetylcholine-induced vasorelaxation was examined.
Kidneys were removed and microvasculature was isolated using
sieving technique exactly as detailed in the previous study [14].
Blood was collected through left ventricular puncture. Renal
vascular lysates and plasma were examined using LC-MS/MS
spectrometry for all detectable metabolites and multiplex analysis.
Serum samples were examined for creatinine concentration
(Cayman, Ann Arbor MI.) and cytokines (multiplex biomarker
analysis using Linco Inc, St. Louis, MO). Daily urine output was
evaluated by sampling urine collected using mouse metabolic
cages. Urine albumin and creatinine concentrations were mea-
sured using enzyme-linked immunosorbent assay (ELISA) and
creatinine kit (Cayman, Ann Arbor MI.) to obtain protein:crea-
tinine ratio.
Acetylcholine-induced Vasorelaxation of Aortic Rings
The descending thoracic aorta from FVB mice, treated or not
treated with L-NMMA and receiving glutamine supplementation,
was segmented into cylindrical segments which were mounted on a
wire-myograph containing Krebs buffer gassed with 95% O2–5%
CO2 for recording of isometric tension [28]; the vessels were
preconstricted with phenylephrine to 70% of maximal response
and used for assessment of acetylcholine (0.001–100 mmol/L)-
induced vasorelaxation.
Untargeted Analysis of Metabolites (50–1000 Daltons)
Plasma samples were diluted 1:20 in 70% acetonitrile/dH2O
containing 0.2% acetic acid. The diluted samples were briefly
vortexed and centrifuged to pellet precipitated proteins. Sample
supernatants were transferred to autosampler vials for analysis by
HPLC-MS and HPLC MS/MS. The LC/MS setup was the same
as described previously [29].
Metabolomics Data Processing and Analysis
Raw data files were processed by Agilent MassHunter
Qualitative Analysis Software and analyzed by statistical analysis
in Mass Profiler Professional as described [29]. (Agilent Technol-
ogy, MPP, version B2.02). Briefly, MassHunter Qualitative2
Analysis untargeted molecular feature extraction (MFE) generates
features (compounds/metabolites) based on the elution profile of
identical mass and retention times, within a defined mass accuracy
(5 ppm). Aligned molecular features detected in all biological
replicates of at least one group were directly applied for statistical
analysis across treatment groups by MPP. The Benjamini
Hochberg FDR correction was applied for multiple testing
correction of p-values in one-way ANOVA (corrected P,0.05).
Uncorrected P-value was used when individual metabolites were
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manually inspected for statistical significance between two group-
s(e.g simple student t-test.).
Differential metabolites were initially searched against an in-lab
annotated METLIN Personal Metabolite Database (Agilent
Technologies), based on accurate monoisotopic neutral masses
(,5 ppm). A molecular formula generator (MFG) algorithm in
MPP was used to generate and score empirical molecular formulae
based on a weighted consideration of monoisotopic mass accuracy,
isotope abundance ratios, and spacing between isotope peaks.
Notably, MFG imposes additional constraints on the list of
candidate molecular formulas detected by a METLIN database
search. A putative compound ID was tentatively assigned when
METLIN and MFGconcurredfor a given candidate. Tentatively
assigned compounds were verified based on a match of LC
retention time and/or MS/MS fragmentation patterns to pure
molecular standards. As no repository exists for metabolomic data,
the authors will make the results of this study available to all
interested researchers.
Circulating Levels of Cyto- and Chemokines
The multiplex mouse cardiovascular diseases biomarkers panel
and the Cytokines/Chemokines panel were used (MCVD1-67AK
4 plex, MCyt/Chem 13Plex, Linco Inc, St. Louis, MO) for the
simultaneous quantification of the following analytes: soluble E-
Selectin (sE-Selectin), soluble ICAM (sICAM-1), soluble VCAM-1
(sVCAM), Matrix Metalloproteinase-9 (MMP-9) and 13 Soluble
Cytokines (MIP-1a, GMCFS, MCP1, KC, RANTES, IFNc,
IL1b, IL1a, GCSF, IP10, IL-10, TNF-a). All examined analytes
had been tested individually and in combination to ensure that
there were no cross-reactions. Briefly, the multibiomarkers and
cytokine standards were resuspended in the assay buffer and then
differentially serially diluted. Twenty-five ml of standard, Quality
Controls or sample were added to each well of a 96-well plate with
25 ml of the bead solution. Each plate was sealed, covered with
aluminum foil and incubated overnight (16–18 h) with agitation
on a shaker platform at 4uC. The plates were washed twice with
200 ml/well of washing buffer, buffer being removed by vacuum
filtration between each wash. This was followed by addition of
25 ml of a detection antibody cocktail into each well and
incubation at room temperature for 1.5 h. Streptavidin-phycoer-
ythrin solution (25 ml) was added to each well and incubated at
room temperature for 30 min. The multianalyte composition was
then analyzed using a LuminexIS100 analyzer (Luminex Inc,
Austin TX). The data were evaluated as Median Fluorescence
Intensity (MFI) using appropriate curve-fitting software (Luminex
100IS software version 2.3). A 5-parameter logistic method with
weighing was used.
Statistical Analysis
All other quantitative data were determined as the mean value
6 SEM. Statistical analyses of data were performed by ANOVA
for multiple-group means or by Student’s t test for comparisons
between two group means. Statistical significance was set at the
level of P,0.05.
Results
Previous studies [14,27] demonstrated that chronic administra-
tion of non-pressor doses of L-NMMA (0.3 mg/ml of drinking
water daily for 2-months) results in a mild endothelial dysfunction.
As shown in Figure 1, this finding was reconfirmed using an ex
vivo aortic ring vasorelaxation assay. Moreover, concomitant
treatment with glutamine at doses 1, 10 and 30 mg/ml of drinking
water, significantly protected against the otherwise impaired
acetylcholine-induced relaxation of aortic rings. This protective
effect of GLN was dose-dependent. In addition, mice receiving L-
NMMA exhibited signs of nephropathy: a mild significant
elevation in serum creatinine and proteinuria (Figure 2). These
findings suggest the existence of a link between the impaired
metabolic state of the vascular endothelium and suppressed nitric
oxide-dependent vasorelaxation associated with the developing
nephropathy.
To further examine this link, we performed similar studies in
caveolin-1(2/2) and caveolin-1 overexpressing transgenic mice. It
is well-established that the function of eNOS is dependent on
caveolin-1 [30]. There is evidence that both manipulations of
caveolin-1 expression result in perturbations of vascular functions
[31] [32,33]. Under basal conditions, aortic rings from caveolin-1
knockout mice, previously shown to overproduce nitric oxide [34]
exhibited a robust vasorelaxation in response to acetylcholine and
this response was not affected by non-pressor doses of L-NMMA
with or without GLN supplementation (Figure 3). In contrast,
aortic rings obtained from caveolin-1 transgenic mice exhibited a
significant suppression of vasorelaxing effect of acetylcholine,
which became even more profound in mice treated with non-
pressor doses of L-NMMA (Figure 3). When these mice were
provided with GLN supplementation, vasorelaxing action of
acetylcholine was partially rescued. These findings provided
additional evidence to support the existence of a link between
the metabolic status of vascular endothelium and nitric oxide-
dependent vasorelaxation.
In view of the previous demonstration of immunomodulatory
effect of GLN, we next sought to examine the possibility of
immunologic effects of GLN supplementation in mice chronically
treated with L-NMMA. Toward this end, multiplex analysis of
cyto- and chemokines was carried out. Levels of interleukins IL1b,
IL-6, as well as MIP-1b, MIP-2, INF-c, and GM-CSF all showed
significant increase in L-NMMA-treated mice (Figure 4). GLN
supplementation on its own did not alter levels of cytokines in
control mice. In contrast, addition of GLN to L-NMMA-treated
mice resulted in a significantly decreased the level of IL-6 and
GM-CSF and blunted (p = 0.1–0.15) L-NMMA-induced elevation
of MIP-1b, MIP-2, INF-c, and soluble E-selectin. These findings
argue in favor of anti-inflammatory effect of GLN supplementa-
tion in L-NMMA-treated mice.
In an attempt to uncover metabolites potentially responsible for
a) L-NMMA-induced ECD and b) GLN rescue of ECD, as judged
by the acetylcholine-induced vasorelaxation, we next performed
metabolomic profiling of plasma and isolated microvascular
samples obtained from control and L-NMMA-treated mice with
or without GLN supplementation. The number of metabolites of
molecular size 50–1000 Da detectable in the plasma of these mice
was as follows: 3453 molecules could be detected with 100%
frequency in mice from at least one treatment group (Figure S1).
Among these molecules, 40 were found to be differentially
expressed in a 4-way comparison of Control vs. L-NMMA vs.
GLN vs. GLN+L-NMMA groups (one-way ANOVA, Benjamini-
Hochberg FDR corrected P,0.05). Principal component analysis
PCA clearly differentiated all treat groups (Figure S1B) and
unsupervised hierarchical cluster analysis revealed a clear and
reproducible pattern of within-group metabolite expression
similarities and between-group differences (Figure S1C). L-
NMMA+GLN and control shared 41 differential metabolites
when compared L-NMMA (Figure S1D, uncorrected P,0.05,
fold change .1.5). To narrow the field of potential candidates for
the observed effects of L-NMMA and glutamine, attention was
focused on those, which showed a reciprocal dynamics between a)
control and L-NMMA and b) L-NMMA and L-NMMA with
Glutamine Alleviates Endothelial Dysfunction
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GLN. Such a strategy has a higher probability of uncovering
metabolite(s) of interest. A group of metabolites fitting these
imposed requirements is presented in Figure 5. Notably, several
lipid metabolites (glycerophosphocholine, glyceroethanolamine,
Figure 1. Chronic administration of glutamine dose-dependently improves the acetylcholine-induced endothelium-dependent
vasorelaxation in L-NMMA-treated mice. Both L-NMMA and glutamine, diluted in drinking water, were administered for 2 months.
doi:10.1371/journal.pone.0065458.g001
Figure 2. Renal function in mice receiving L-NMMA and treated with L-glutamine. The graphs summarize results of serum creatinine and
albumin:creatinine ratio in the urine of control mice and mice receiving a non-pressor dose of L-NMMA with and without 1, 10, and 30 mg/ml L-
glutamine. Note that glutamine alone had no effect on either of these parameters of renal function under control conditions. Mice receiving L-NMMA
had a mild elevation in serum creatinine and proteinuria. Those animals which were simultaneously treated with L-glutamine at 10 and 30 mg/ml (but
not 1 mg/ml) showed normalization of both parameters of renal function.
doi:10.1371/journal.pone.0065458.g002
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lysophosphatidylethanolamines [22:6 and 18:2]) and hippuric acid
exhibited the required dynamics.
Metabolic profiling of renal microvasculature detected 1400
aligned features in all 6 replicates of at least one treatment group
by untargeted molecular feature extraction (Figure S2A).
Principal component score plot analysis showed an L-NMMA-
dependent clustering and separation of control and treatment
groups (Figure S2B). Unsupervised hierarchical clustering
showed clustering and branching of mouse kidney vessel
metabolites by GLN treatment (Figure S2C). As summarized
by the Venn diagram, 37 differential metabolites in L-
NMMA+GLN vs L-NMMA and Control vs L-NMMA (uncor-
rected P,0.05, fold change.2) were shared. L-NMMA-induced
renal microvascular metabolite changes that were offset by GLN
supplementation (Figure 6) included myoinositol, GPC, betaine,
and taurine (four different renal organic osmolytes which provide
the safety factor of redundancy of their protective effect on kidney
function). Notably, taurine was the only osmolyte up-regulated in
L-NMMA-treated mice (as compared to down-regulation of GPC,
betaine and myoinisitol) and compensated by GLN treatment.
GABA and alanine, potential inhibitors of taurine transport, were
also down-regulated in L-NMMA treated mice.
Hippuric acid is a well-known ‘‘uremic toxin’’ [35], thus its
elevation in non-uremic mice, albeit with endothelial cell
dysfunction, was unexpected. To ascertain potential effects of
hippuric acid on vasomotion, in the next series of experiments we
employed thoracic aortic rings to examine its vasoconstrictor
effects and its influences on vasorelaxation. Addition of hippuric
acid at concentrations of 100 um-1 mM to the incubation bath did
not produce vasoconstriction (not shown). In contrast, hippuric
acid significantly and dose-dependently attenuated acetylcholine-
induced relaxation of aortic rings (Figure 7). These findings
establish the hitherto unknown action of hippuric acid, a putative
‘‘uremic toxin’’, to alter vasorelaxation of large vessels. These
observations provide a potential link between the accumulation of
hippuric acid, even in pre-uremic animals, and the early
development of vasculopathy.
Figure 3. Glutamine supplementation dose-dependently im-
proves acetylcholine-induced vasodilatatory response of tho-
racic aortic rings in caveolin-1 transgenic but not in knock-out
mice. +p,0.05; KO vs. TG (same treatment; only Ach 0.1 mM, 1 mM,
10 mM). ˆp,0.05; KO (Ctrl, L-NMMA, L-NMMA+Glutamine) vs. Ach
0.1 mM, 1 mM, 10 mM *p,0.05; TG (Ctr) vs. Ach 0.1 mM, 1 mM, 10 mM
n=6.
doi:10.1371/journal.pone.0065458.g003
Figure 4. Results of cyto2/chemokine screening of plasma in
mice receiving L-NMMA and treated with 30 mg/ml L-gluta-
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Discussion
Data presented herein establish that in mice with isolated
endothelial cell dysfunction induced by chronic administration of
non-pressor doses of L-NMMA GLN supplementation ameliorates
impaired vasorelaxation and proteinuria, blunts elevation in the
level of ‘‘uremic toxin’’ hippuric acid, and mitigates elevation in
pro-inflammatory cytokines.
Though it was not the purpose of this study to examine
molecular mechanisms of GLN action, the previously described
contribution of GLN to glutathione synthesis and its maintenance
in reduced form by providing a source of reducing equivalents like
NADPH [36] is highly relevant to the present dataset. A similar
end-effect can be observed in erythrocytes, where GLN plays a
role of antioxidant and preserves NADPH level required for
glutathione recycling [37]. Consistent with our previous demon-
stration of enhanced oxidative stress in the L-NMMA model of
endothelial cell dysfunction [14], the above-mentioned antioxidant
defense by GLN supplementation can explain some of the
observed benefits of this therapy: prevention of eNOS uncoupling
and generation of peroxynitrite. An additional potential mecha-
nism of beneficial vascular effect of GLN supplementation can be
the consequence of restored Krebs cycling of intermediates with
the activation of malate shuttle and enhanced production of
NADPH, a co-factor of endothelial nitric oxide synthase.
Furthermore, the ability of GLN to be converted to L-citrulline
[38], with the latter converted to L-arginine, may underlie the
observed restoration of endothelium-dependent vasorelaxation.
Such a necessity may occur in situations accompanied by
uncoupling of eNOS, as it occurs in cultured porcine aortic
endothelial cells where L-NMMA stimulated L-arginine efflux via
y+ transporter, potentially depleting its intracellular pool [39] and
further exacerbating eNOS uncoupling.
The whole subject of GLN effects on eNOS is strewn with
controversies. Early studies demonstrated that GLN inhibits
release of endothelium-derived relaxing factor [40], but did not
interfere with the uptake of L-arginine, rather inhibited its
generation [41]. In cultured endothelial cells and in aortic rings,
L-glutamine inhibited bradykinin-induced NO production, but
increased NO production in response to a calcium ionophore; in
either case effect was not due to modulation of eNOS activity [42].
In rat aortic rings, however, L-glutamine increased NO formation
and vessel relaxation in eNOS-dependent manner [43]. In rabbits
with thromboxane-A2 mimetic-induced pulmonary hypertension,
GLN administration increased pulmonary artery pressure, but the
mine. Experiments were performed using a Luminex platform allowing
detection of 21 cyto2/chemokines listed in the Methods. Only those
components of the screen that showed statistically significant
differences between the groups are depicted.
doi:10.1371/journal.pone.0065458.g004
Figure 5. LNMA-induced plasma lysophospholipid changes that were offset by glutamine. Bioactive lysophosphocholines are involved in
key pathobiological processes associated with vascular disease. Several lipid metabolites (glycerophosphocholine, glyceroethanolamine,
lysophosphatidylethanolamines [22:6 and 18:2]) and hippuric acid exhibited the required dynamics.
doi:10.1371/journal.pone.0065458.g005
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opposite effect was documented in animals pretreated with L-
NMMA [44].
In rats on cardio-pulmonary bypass, GLN administration
reduced plasma levels of IL-6 and IL-8, improved myocardial
respiration, increased the levels of HSP-70, preserved the activity
of eNOS and attenuated induction of iNOS [45]. Notwithstanding
these uncertainties generated in cultured cells or in acute
experiments, in our case of chronic inhibition of NO production,
GLN supplementation alleviated vasculopathy, reduced pro-
inflammatory cytokines, and improved microcirculatory functions,
as judged from the reduced proteinuria and serum creatinine.
One of the unexpected findings of untargeted metabolomic
analysis is related to the L-NMMA-induced reduction of vascular
GLN. In this vein, peroxynitrite, a constantly elevated by-product
of endothelial dysfunction, decreases the activity and expression of
glutamine synthetase due to nitration of tyrosine residues in the
active site [46]. Moreover, GLN consumption may be elevated in
mice with chronic L-NMMA treatment to compensate for the
reduced reduced cellular L-arginine levels [39], and the develop-
ing deficiency is prevented by GLN supplementation, thus
preserving its level and above-mentioned functions.
In patients with chronic kidney disease, the level of hippuric
acid increases from 2.2 mM in control to 160 mM in far-advanced
disease [47]. Hippurate has been shown to inhibit glucose
utilization in striated muscles [48] thus contributing to muscle
weakness and to accelerate the progression of chronic kidney
diseases [49]. Since the renal excretion of hippurate represents the
major pathway for its elimination [50], the finding of its elevation
in our non-uremic mice displaying only mild renal impairment
Figure 6. LNMA-induced kidney blood vessel metabolite changes that were offset by glutamine. L-NMMA-induced renal microvascular
metabolite changes that were offset by GLN supplementation included myoinositol, GPC, betaine, and taurine wich was the only osmolyte up-
regulated in L-NMMA-treated mice (as compared to down-regulation of GPC, betaine and myoinisitol) and compensated by GLN treatment. GABA
and alanine, potential inhibitors of taurine transport, were also down-regulated in L-NMMA treated mice.
doi:10.1371/journal.pone.0065458.g006
Figure 7. Hippuric acid dose-dependently suppresses acetyl-
choline-induced vasorelaxation of aortic rings. Thoracic aortic
rings were incubated in the presence of hippuric acid during
equilibration period and then subjected to escalating concentrations
of acetylcholine. *p,0.05 vs. Control & Hippuric Acid (500 mM)ˆp,0.05
vs. Control, n = 4.
doi:10.1371/journal.pone.0065458.g007
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was rather unexpected. Similarly unexpected, but consistent with
our findings, was the mass-spectrometric detection of elevated
levels of hippuric acid released by the human vascular wall
subjected to inflammation and oxidative stress as occurs in
athrothrombotic aneurismal areas [51]. These and our findings
argue in favor of the increased metabolic rate of hippurate
synthesis during syndromes associated with endothelial cell
dysfunction.
Notably, L-NMMA treatment failed to alter plasma levels of
Krebs cycle intermediates, suggesting that the ECD-associated
Krebs cycle suppression in renal vasculature may be relatively
restricted to the vascular endothelium and insufficient to globally
influence metabolite levels in the circulation. This is not entirely
surprising. Although it is currently impossible to detect the actual
size and any potential improvement in the a-ketoglutarate and
other intermediates’ pool (according to Krebs, ‘‘the fate of the
label does not allow predictions to be made about the net fate of
the labeled metabolites’’), relative levels can be assessed based on
the functional improvement [52]. This functional improvement
was precisely what we have demonstrated here: GLN supplemen-
tation reduced manifestations of vasculopathy and pro-inflamma-
tory profile associated with endothelial cells dysfunction.
In conclusion, GLN supplementation in mice with endothelial
cell dysfunction improves vasculopathy, nephropathy and a profile
of circulating pro-inflammatory mediators. Curiously, endothelial
dysfunction per se causes GLN deficiency, thus explaining in part
the beneficial effect of its supplementation. Based on these findings
and previous investigations by others, we propose an up-dated
mechanistic explanation of the observed effects of GLN supple-
mentation on microvascular function in L-NMMA-treated mice
(Figure 8). The pathways potentially involved in the observed
end-effect of GLN supplementation of L-NMMA-treated mice
with endothelial dysfunction include the cytosolic (replenishing
GLN level), systemic (anti-inflammatory, reduction of hippuric
acid) and possibly mitochondrial (Krebs cycle) components. Based
on these findings, we are currently initiating pilot clinical studies of
glutamine supplementation in patients with chronic kidney
diseases. In addition, data show that plasma metabolite profiling
offers the potential to provide a molecular definition of ECD,
diagnose ECD subtypes, assess severity and monitor the efficacy of
new therapies. Furthermore, it has a potential to disclose hitherto
unknown mediators of progression of disease, as is the case with
the discovery of 1) GLN deficiency in mice with endothelial
dysfunction and 2) hippuric acid elevation long before the uremic
stage of kidney disease, both contributing to developing vasculo-
pathy and organ failure.
Note: After this paper was accepted for the publication, 2
relevant papers have been published. Jeong and colleagues [53]
demonstrated that DNA damage response is associated with
decreased glutamine/glutamate conversion into alpha-ketogluta-
rate via sirtuin-4-dependent inhibition of glutamate dehydroge-
nase. This response is required for the DNA-damaged cell to enter
cell cycle arrest. Reid et al. [54] demonstrated that glutamine
deprivation results in reduction of reduced glutathione, increased
oxidative stress and activation of transcription factor p53. Both
described pathways of glutamine deficiency-induced cell cycle
arrest and p53 activation may be relevant to the proposed
mechanisms of action of glutamine supplemetation in dysfunc-
tional endothelial cells.
Supporting Information
Figure S1 Metabolite profiling identifies differentially expressed
metabolites among untreated mouse plasma and treatment groups
of LNMA, glutamine, LNMMA+glutamine. (A) 3453 aligned
features were detected in all 6 replicates of at least one treatment
group by untargeted molecular feature extraction. 40/3453 were
found to be differentially expressed in a 4-way comparison of
Control vs. L-NMMA vs. GLN vs. GLN+L-NMMA groups (one-
way ANOVA, Benjamini-Hochberg FDR corrected p,0.05) (B)
PCA score plot shows a drug-dependent clustering and separation
of treatment groups and control using the 40 metabolites from
one-way ANOVA. (C) Unsupervised hierarchical clustering shows
clustering and branching of mouse plasma by glutamine
treatment. (D)Venn diagram shows 41 shared differential
metabolites in LNMA+Glutamine vs LNMA and Control vs
LNMA (uncorrected P,0.05, fold change .1.5).
(TIF)
Figure S2 Metabolite profiling identifies differentially expressed
metabolites among mouse kidney vessels of untreated group and
treatment groups of LNMA, glutamine, LNMA+glutamine. (A)
1400 aligned features were detected in all 6 replicates of at least
one treatment group by untargeted molecular feature extraction.
(B) PCA score plot shows a drug-dependent clustering and
separation of treatment groups and control. (C) Unsupervised
hierarchical clustering shows clustering and branching of mouse
kidney vessel metabolites by glutamine treatment. (D) Venn
diagram shows 37 shared differential metabolites in LNMA+Glu-
tamine vs LNMA and Control vs LNMA (uncorrected P,0.05,
fold change .2.0).
(TIF)
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Figure 8. Cartoon summarizing major functional and metabolomic findings and proposed pathways of L-glutamine
supplementation-induced amelioration of vascolopathy (see text for the details).
doi:10.1371/journal.pone.0065458.g008
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